TNF and rheumatoid arthritis: Rheumatoid arthritis (RA) is a debilitating inflammatory condition that primarily affects the joints, reducing physical function and quality of life.1 Globally, approximately 20 million people have RA.2 Tumor necrosis factor-α inhibitors (TNFIs), such as infliximab, adalimumab, and etanercept, are biologic disease-modifying antirheumatic drugs used worldwide to treat RA.3,4,5,6 While robust evidence has demonstrated the efficacy and safety of TNFIs for managing RA, the high costs of TNFIs can limit treatment access to these drugs worldwide.6,7